bicalutamide has been researched along with belinostat in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Di Cesare, E; Festuccia, C; Gravina, GL; Jannini, EA; Lenzi, A; Mancini, A; Marampon, F; Motta, M; Muzi, P; Negri-Cesi, P; Piccolella, M; Tombolini, V | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
2 other study(ies) available for bicalutamide and belinostat
Article | Year |
---|---|
PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Castration; Cell Line, Tumor; ErbB Receptors; Exportin 1 Protein; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Karyopherins; Male; Mice; Mice, Nude; Nitriles; Phenotype; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Androgen; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Tosyl Compounds | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |